Young Kwang Chae on Muck Rack

Young Kwang Chae

Chicago, Houston
As seen in: Color Research & Application, Nature, Wiley Online Library, The Oncologist, Chicago Tribune, Chicago Tribune Opinion, The BMJ, Pioneer Press, Richmond Times-Dispatch, Yakima Herald-Republic and
Medical Oncologist, Translational Physician-Scientist, Professor, Co-Director of Developmental Therapeutics Lurie Cancer Center at Northwestern University
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Young Kwang

Contact Young Kwang, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort

|
By Sandip Patel, Young Kwang Chae, Luisa Solis Soto
| The BMJ Verified
Pancreatic neuroendocrine neoplasms are rare tumors with low response rates to anti-programmed cell death protein-1 immunotherapy Nivolumab combined with low-dose ipilimumab demonstrated a clinical benefit rate (includes stable disease >6 months plus objective response) of 26% with durable benefit lasting >2 years in 3 of 19 patients. These results suggest that dual immunotherapy may be useful for a subset of patients with this rare cancer and that additional investigations are warranted.
Open in Who Shared Issue with article?

Razelle Kurzrock: Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors

|
By Young Kwang Chae, Megan Othus, Sandip Patel, Charles D. Blanke
| OncoDaily
Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center, shared a post on X about her recent article published in Journal for ImmunoTherapy of Cancer.
Open in Who Shared Issue with article?

Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors

|
By Young Kwang Chae, Megan Othus, Sandip Patel, Benjamin Powers
| The BMJ Verified
Discussion Currently, there is limited prior experience with immunotherapy in the treatment of desmoid tumors. To our knowledge, this is the first study to prospectively evaluate the response of desmoid tumor to isolated ICI therapy. Ipilimumab combined with nivolumab showed a trial response rate of 18.8% (3/16) and CBR of 62.5% (10/16).
Open in Who Shared Issue with article?
See all 23 licensed articles (27 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified